By: Daniel Trecroci
Novocell, Inc., a San Diego, California-based stem cell engineering company, announced on October 19, 2006, the development of a process that “efficiently converts human embryonic stem cells into insulin-producing pancreatic endocrine cells.”
“Such an approach could provide a means to produce sufficient quantities of insulin-producing cells for transplantation into patients with type 1 diabetes,” writes Novocell in a press release, “a treatment that offers a potential therapy for this disease.”
* * *
Source: Novocell, Inc.